Product Details
| Product Name:
Atezolizumab |
CAS No.:
1380723-44-3 |
| Purity:
95.20% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | Atezolizumab |
| Description | Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells. |
| Cell Research | Objective: Determine the binding of [111In]PD-L1-mAb to tumor cell lines. Cells: NCI-H2444（Lung Cancer cell line）, MDAMB231（Breast Cancer cell line）,etc. Concentrations: 1 μCi/100μl. Incubation Time: 1 h. Method: Incubating 1 μCi of [111In]PD-L1-mAb with 1×106cells (in triplicate for each cell line) for 1h at 37°C. PD-L1 blocking was performed by adding a 10-fold molar equivalent excess of the non-labeled mAb. After incubation, cells were washed three times with cold PBS prior to counting on an automated gamma counter. |
| In vitro | METHODS: MDA-MB-231, BT-20, MDA-MB-468 cells and T cells were co-cultured and treated with Atezolizumab (50-100 μg/mL) for 4-24 h. T cell-mediated cytotoxicity assay was performed.
RESULTS: Atezolizumab significantly enhanced T cell-mediated cytotoxicity of MDA-MB-231 cells in a dose-dependent manner, with 100 μg/mL concentration of Atezolizumab showing significant efficacy at 4 and 24 h incubation.Similar results were obtained with BT-20. No Atezolizumab-induced T cell-mediated cytotoxicity was observed in PD-L1- MDA-MB-468 cells compared to MDA-MB-231 and BT-20 cells. [1]
METHODS: MDA-MB-231 cells were treated with Atezolizumab (0.5 μg/mL) for 24 h. Surface expression of PD-L1 was detected by flow cytometry.
RESULTS: Almost all MDA-MB-231 cells were positive for PD-L1, but the detection of PD-L1 epitopes was blocked by the specific antibody Atezolizumab after 24 h treatment. [2] |
| In vivo | METHODS: To detect in vivo antitumor activity, Atezolizumab (10 mg/kg) and Bevacizumab (5 mg/kg) were intraperitoneally injected into BALB/C nude mice bearing A2780cis xenografts every two days for three weeks.
RESULTS: In vivo treatment with Atezolizumab or Bevacizumab induced significant antitumor effects and significantly inhibited tumor growth. Dual blockade with Atezolizumab and Bevacizumab significantly inhibited tumor growth compared to each treatment. [3] |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
| Keywords | Inhibitor | MPDL3280A | inhibit | Apoptosis | Atezolizumab | Autophagy |
| Inhibitors Related | Stavudine | Meclizine dihydrochloride | Sodium 4-phenylbutyrate | L-Ascorbic acid | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Tributyrin | Curcumin | Paeonol | Naringin | Gefitinib |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:5355-16-8
$42.00 / 500mg
-
CAS:2158197-70-5
$48.00 / 1mg
-
CAS:912758-00-0
$88.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States